source
- Johnson & Johnson shares drop 6% after earnings meet forecasts but show weak medical device outlookJohnson & Johnson reported third‑quarter results that met Wall Street expectations and raised its 2026 financial guidance, yet the stock fell about 6% on the day. Analysts highlighted an underwhel…
- Verastem reports promising early results for KRAS G12D inhibitor in pancreatic and lung cancersVerastem Oncology has shifted its research toward a KRAS G12D inhibitor, VS-7375, and released early data from a phase 1/2 study involving more than 200 patients with advanced KRAS G12D-mutated sol…